Patents Assigned to Hadasit Medical Research Services and Development Ltd.
  • Patent number: 10933031
    Abstract: The current invention is a method of preventing and treating certain diseases by preventing the synthesis and/or breakdown of glycogen by the administration of an agent, guaiacol. Diseases that can be prevented and treated by the administration of guaiacol include but are not limited to glycogen storage disease type IV (GSD-IV), adult polyglucosan body disease (APBD), and Lafora disease (LD). The invention also includes methods and tools for screening for agents that prevent and treat these diseases as well as basic research, specifically in the form of cells and cell lines that produce detectable polyglucosan.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 2, 2021
    Assignees: The Trustees of Columbia University in the City of New York, Hadasit Medical Research Services and Development Ltd., Ramot at Tel-Aviv University, Ltd.
    Inventors: Hasan Orhan Akman, Salvatore Dimauro, Or Kakhlon, Miguel Enrique Weil
  • Patent number: 10918677
    Abstract: The present invention provides attenuated or inactivated pathogenic bacteria having anti-cancer properties, compositions comprising the bacteria, and use thereof for treating cancers of the urogenital system.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: February 16, 2021
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Ofer Mandelboim, Gilad Benjamin Bachrach, Chamutal Gur, Vladimir Yutkin
  • Publication number: 20210015889
    Abstract: Methods of disrupting a biofilm and/or preventing formation of a biofilm are provided. Accordingly there is provided a method of reducing or preventing formation of a biofilm and/or disrupting a biofilm comprising contacting a biofilm-producing microorganism with a carbonic anhydrase inhibitor; a urease inhibitor; a Ca2+ ATPase inhibitor; a tlp activator; and/or a myo-inositol catabolism pathway activator. Also provided are articles of manufacture and methods of treating a medical condition in which disrupting a biofilm and/or preventing formation of same is beneficial and methods of predicting or increasing sensitivity to an anti-microbial agent.
    Type: Application
    Filed: September 29, 2020
    Publication date: January 21, 2021
    Applicants: Yeda Research and Development Co. Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Ilana KOLODKIN-GAL, Alona KEREN-PAZ, Eitan KEREM, Gideon ZAMIR, Dror KOLODKIN-GAL, Malena COHEN-CYMBERKNOH
  • Patent number: 10874114
    Abstract: Provided are microvesicles isolated from milk, compositions thereof and uses for the preparation of milk formulas. Further provided are microvesicles, including exosomes and/or fat globules which encapsulate various miRNA molecules and uses thereof, as exemplified by supplementing milk formulas.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: December 29, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Shimon Reif, Regina Golan
  • Patent number: 10828308
    Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering from type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: November 10, 2020
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Yaron Ilan, Doina Cosma Roman, Michael Hayden, Einat Amit-Romach
  • Patent number: 10814018
    Abstract: The present invention provides isotopically labeled deoxy-glucose and derivatives thereof, methods of their preparation, ration, kits comprising them and uses thereof for spin hyperpolarized magnetic resonance imaging, utilized in the quantitative and qualitative diagnosis of states, conditions, diseases, or disorders in the body of a subject.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: October 27, 2020
    Assignee: HADASIT MEDICAL RESEARCH SERVICE & DEVELOPMENT LTD.
    Inventors: Moshe Gomori, Hyla Allouche-Arnon, Rachel Katz-Brull
  • Patent number: 10710968
    Abstract: Radiolabeled compounds which are erlotinib analogs that feature a radioactive halogen and processes of preparing same are disclosed. Uses of these radiolabeled compounds in radioimaging, for identifying and monitoring a level, distribution and/or mutational status of deregulated EGFR, and/or in radiotherapy, are also disclosed.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: July 14, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Eyal Yosef Mishani, Ofer Shamni, Galith Rachel Abourbeh-Gofrit
  • Patent number: 10695270
    Abstract: Ostomy tubes, particularly gastrostomy tubes, with improved retention means are provided. More specifically, retention structures, such as bolsters, for gastrostomy tubes are provided, configured to removably assemble to one end of a gastrostomy tube to facilitate replacement and removal of the tube. The retention structures provided herein may comprise one or more removably assembled retention elements. Further provided are gastrostomy tubes comprising such retention structures, and methods for percutaneous endoscopic gastrostomy utilizing same.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: June 30, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Ishay Benuri-Silbiger
  • Publication number: 20200171215
    Abstract: Methods are provided for promoting cartilage growth and/or repair. The methods include, administering locally to a site in a subject in need thereof, bone marrow stromal cells attached to fibrin microbeads comprising crosslinked hyaluronic acid and thereby producing stable cartilage locally at the site in the subject.
    Type: Application
    Filed: May 31, 2018
    Publication date: June 4, 2020
    Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Pamela Gehron Robey, Sergei Kuznetsov, Raphael Gorodetsky, Astar Hailu-Lazmi, Mitchell Shirvan, Joseph Featherall
  • Publication number: 20200165671
    Abstract: A method of determining the methylation status of at least one methylation site of a double-stranded DNA molecule is disclosed. The method comprises analyzing the methylation status of both the forward strand and the reverse strand of the DNA molecule.
    Type: Application
    Filed: July 13, 2018
    Publication date: May 28, 2020
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Yuval DOR, Ruth SHEMER, Benjamin GLASER, Judith MAGENHEIM
  • Patent number: 10617697
    Abstract: A vitamin D2-enriched biomass of an edible fungus, extracts and compositions thereof are provided, for use in delaying onset of, treating, ameliorating or protecting from an immune-related or inflammatory related disease, disorder or condition, wherein the level of vitamin D2 in said biomass is at least 80 IU/gr.
    Type: Grant
    Filed: January 17, 2016
    Date of Patent: April 14, 2020
    Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD
    Inventors: Dan Levanon, Yaron Ilan, Ofer Danai
  • Patent number: 10611798
    Abstract: The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: April 7, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rachel Bar-Shavit
  • Patent number: 10611821
    Abstract: This application describes a method of delivering a TNF antagonist molecule, in a biologically active form, to a subject in need thereof, the method comprising, orally or mucosally administering to the subject a therapeutically effective amount of a TNF antagonist molecule. This application further describes a method of treating, preventing or reducing liver diseases, the method comprising, administering to the subject a therapeutically effective amount of a TNF antagonist molecule.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: April 7, 2020
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventor: Yaron Ilan
  • Publication number: 20200061355
    Abstract: A method for influencing cerebral perfusion in a patient by modifying a volume of a volume adaptor introduced into a cerebral ventricle of the patient, the method comprising identifying a timing of a cerebral blood inflow and/or outflow in a cardiac activity of the patient, modifying a volume of the volume adaptor in synchronization to the identified timing of the cerebral blood flow, to an amount sufficient to modify an intracranial pressure in the cerebral ventricle, such that a flow of the cerebral blood flow is enhanced. In some exemplary embodiments of the invention, the inflation duration of the volume adapter is short relative to the cardiac cycle.
    Type: Application
    Filed: November 16, 2017
    Publication date: February 27, 2020
    Applicants: Ramot at Tel-Aviv University Ltd., Tel HaShomer Medical Research Infrastructure and Services Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Ofer BARNEA, Omer DORON
  • Publication number: 20200032204
    Abstract: A method of generating photoreceptor cells is disclosed. Cell populations comprising photoreceptor cells and uses thereof are also disclosed.
    Type: Application
    Filed: February 8, 2018
    Publication date: January 30, 2020
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin E. Reubinoff, Masha Gorshtein, Hanita Khaner, Alex Obolensky, Eyal Banin
  • Patent number: 10525009
    Abstract: The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: January 7, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Itzhak E. Lerner, Moshe Flashner-Barak, Erwin v Achthoven, Hans Keegstra, Ruud Smit
  • Publication number: 20190389948
    Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
    Type: Application
    Filed: May 9, 2019
    Publication date: December 26, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat SAFADI
  • Patent number: 10500226
    Abstract: Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than ?25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10?8 cm2/second, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease; liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: December 10, 2019
    Assignees: Hadasit Medical Research Services and Development Ltd., B.G. Negev Technologies & Applications Ltd., at Ben-Gurion University
    Inventors: Smadar Cohen, Yaron Ilan, Eyal Shteyer, Ami Ben-Ya'Acov
  • Patent number: 10478476
    Abstract: A method of promoting nerve growth or regeneration in a subject in need thereof, wherein the subject is not afflicted with a substantial connective tissue damage, is provided. The method comprises administering to the subject a therapeutically effective amount of full-length amelogenin, thereby promoting nerve growth or regeneration in the subject.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: November 19, 2019
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Amir Haze, Anat Blumenfeld, Dan Deutsch
  • Publication number: 20190330303
    Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Application
    Filed: May 20, 2019
    Publication date: October 31, 2019
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD
    Inventors: Abraham RUTENBERG, Ronny UZANA, Michal LOTEM, Arthur MACHLENKIN, Galit EISENBERG, Tamar PERETZ-YABLONSKY, Shoshana FRANKENBURG, Roni ENGELSTEIN